Skip to main content

August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective

The Cost of Lung Cancer at the End of Life: Early Institution of Palliative Care Improves Survival
Caroline Helwick
Read More
Why Hasn’t Genomic Testing Changed the Landscape?
Caroline Helwick
Read More
Radiotherapy-Related Hospital Admissions Are Frequent
Read More
Metastatic Colorectal Cancer: Prolonged Bevacizumab Improves Outcomes, New Targeted Therapies on the Horizon
Caroline Helwick
Read More
Patients Willing to Pay for Genetic Testing to Assess Cancer Risk
Read More
Renal-Cell Carcinoma, Oncology
Axitinib Dose Titration Up Enhances Outcomes in Metastatic Renal-Cell Carcinoma
Wayne Kuznar
Read More
Is Biomarker Testing in NSCLC Cost-Effective?
Caroline Helwick
Read More
Lung Cancer, Oncology
Non–Small-Cell Lung Cancer Testing Can Be Offered Routinely in Community Hospitals
Wayne Kuznar
Read More
Renal-Cell Carcinoma, Oncology
Quality of Life Drives Patient Preference for Metastatic RCC Drug
Wayne Kuznar
Read More
Lung Cancer, Oncology
Afatinib Boosts PFS in EGFR Mutation–Positive Lung Cancer
Wayne Kuznar
Read More
Page 3 of 4
Results 21 - 30 of 33